Bassett JT, Rodriguez B, Mulligan L, Fontana RJ. Acute liver failure in a military recruit treated with valproic acid and harboring a previously unrecognized POLG-1 mutation.
Epilepsy Behav Rep 2019;
12:100342. [PMID:
31799506 PMCID:
PMC6883298 DOI:
10.1016/j.ebr.2019.100342]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2019] [Revised: 10/13/2019] [Accepted: 10/18/2019] [Indexed: 02/07/2023] Open
Abstract
Patients with mutations in the POLG-1 gene often are afflicted with drug-resistant seizures at an early age and have an increased risk of valproic acid-induced acute liver failure. Severe valproate hepatotoxicity most commonly arises in children within the first 3 months of treatment with an overall estimated incidence of 1 in 40,000 treated patients. Due to high mortality rates among transplanted children, many experts consider valproic acid-induced acute liver failure in patients with mitochondrial disorders to be a contraindication to liver transplant. We report the successful use of liver transplantation in a young man with valproic acid-associated acute liver failure harboring a previously unrecognized POLG-1 mutation.
Patients with mutations in the POLG-1 gene often have an increased risk of valproic acid (VPA) induced acute liver failure.
Severe valproate hepatotoxicity most commonly arises in children within the first 3 months of treatment.
Many experts consider VPA induced acute liver failure with mitochondrial disorders a contraindication to liver transplant.
We report a case of acute liver failure associated with VPA treated successfully with a liver transplant
Collapse